Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA2 | P47869 | 15/20 | 0.85 |
| ▸ | GABRB2 | P47870 | 15/20 | 0.85 |
| ▸ | MLYCD | O95822 | 1/20 | 0.66 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | CDC7 | O00311 | 1/20 | 0.48 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.48 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23027867 | 0.92 | GABRA2 (1.00) | GABRA2GABRB2MLYCDPTGS2 | |
| SCHEMBL5783286 | 0.90 | GABRA2 (0.80) | GABRA2GABRB2MLYCDPTGS2 | |
| SCHEMBL13437647 | 0.90 | GABRA2 (0.95) | GABRA2GABRB2MLYCDPTGS2 | |
| SCHEMBL5783585 | 0.89 | GABRA2 (0.83) | GABRA2GABRB2MLYCDPTGS2 | |
| SCHEMBL13437658 | 0.86 | GABRA2 (0.83) | GABRA2GABRB2MLYCDPTGS2 | |
| SCHEMBL13437646 | 0.84 | GABRA2 (0.83) | GABRA2GABRB2MLYCDPTGS2 | |
| SCHEMBL5782234 | 0.83 | GABRA2 (0.57) | GABRA2GABRB2MLYCDPTGS2NTSR1 | |
| SCHEMBL15997584 | 0.82 | GABRA2 (0.76) | GABRA2GABRB2MLYCDPTGS2 | |
| SCHEMBL1438305 | 0.82 | GABRA2 (1.00) | GABRA2GABRB2PTGS2 | |
| SCHEMBL26986734 | 0.81 | GABRA2 (0.71) | GABRA2GABRB2MLYCDPTGS2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060189591-A1 | Five-membered heterocyclic derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-08-24 | — | — | US | disclosed |
| EP-1621537-A1 | FIVE-MEMBERED HETEROCYCLIC DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-02-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189591-A1 | Five-membered heterocyclic derivative | PTGS1, PTGIS, PTGS2 | GABRA2 3363/4885GABRB2 3006/4885MLYCD 2910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.